Astrazeneca has scored a hit with Imfinzi in the Caspian trial, but the results are unlikely to endanger Roche's Tecentriq.
The data are positive, but might not do much for the company’s sales.
The latest cut of data from a trial of Amgen’s closely watched Kras inhibitor AMG 510 contains more encouraging signals in lung cancer, though some of the loftiest hopes…
Among small-molecule approaches Europe’s premier oncology conference gives star billing to three Parp inhibitors in ovarian cancer.
Amarin is plugging a change in ESC guidelines to include Vascepa, but with the product’s regulatory fate undecided how much difference will this make to sales?
A collection of all of Vantage's coverage from the 2019 European Society of Cardiology meeting.
Carmat says its artificial heart is the best such device in existence. But time is short, and so is money.
With decent efficacy and clean safety in the Orion-11 trial, questions now turn to pricing and whether The Medicines Company will be taken out.
An increased risk of bleeding outweighs Brilinta’s benefits in a primary prevention population, but there might be a way forward in a patient subgroup.